Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cannabis Use in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03617692
Recruitment Status : Recruiting
First Posted : August 6, 2018
Last Update Posted : March 9, 2020
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The goal of this study is to determine the feasibility of a human observational study of orally administered cannabis use among cancer patients.

Condition or disease
Solid Tumor, Adult

Detailed Description:
Tightly controlled experimental laboratory studies (e.g., clinical trials with randomization) using Cannabis products available in state-regulated markets are simply, at this point, not possible owing largely to federal law and the University requirements related to the Controlled Substances Act and Drug Free Schools and Communities Act. Because a traditional clinical trial design is not possible given the current federal status of Cannabis products, this investigator will use a patient-oriented, prospective observational design. Specifically, individuals who have already decided to try Cannabis for their cancer treatment-related symptoms will initiate use of an orally administered product they have selected. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. The participants will then purchase the product and decide how often and how much to use. This approach is consistent with federal law and supported by our preliminary and ongoing studies(1R01AT009541-01, 1R01DA044131-01, CDPHE2902, R01DA039707). Patients will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks, at which time they will be scheduled for their session in our mobile pharmacology and phlebotomy lab (Ta1-Tc1) so that we may examine the acute effects of the product. The Mobile Lab session will take place at a location of their choosing up to 90 minutes drive-time away from the CUChange Lab. The final follow-up will be one month later via an online survey sent directly to the participant via email.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effects of Cannabis Use in Cancer Patients: A Feasibility Study
Actual Study Start Date : December 4, 2018
Estimated Primary Completion Date : December 20, 2020
Estimated Study Completion Date : December 20, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Group/Cohort
Oral Cannabis
This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.



Primary Outcome Measures :
  1. Likelihood of Accruing Participants: Feasibility of Enrollment [ Time Frame: 18 months ]
    Enroll a minimum of 30 patients and demonstrate reasonable compliance with study procedures within six months of active recruiting.


Other Outcome Measures:
  1. Amount of Interest [ Time Frame: 18 months ]
    Study officials will document how many patients contact the research team regarding their participation in the study

  2. Eligibility [ Time Frame: 18 months ]
    Study officials will document how many patients are and are not eligible to participate in the study.

  3. Enrollment [ Time Frame: 18 months ]
    Study officials will document how many patients actually proceed to enrollment in the study.

  4. Completion of Assessments [ Time Frame: Baseline to one month follow up, in an eighteen month time frame ]
    Study officials will document how many participants complete each assessment (baseline assessment, pre-acute cannabis use assessment, 1 hour post-acute cannabis use, 2 hour post-acute cannabis use, one month follow up assessment).

  5. Study Completion [ Time Frame: 18 months ]
    Study officials will document how many participants complete the study in its entirety.


Biospecimen Retention:   Samples Without DNA
Whole blood sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male or females, ages 21 and up, with a diagnosis of any solid tumor type who has or is undergoing either curative or palliative treatment
Criteria

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Provision to sign and date the consent form.
  2. Stated willingness to comply with all study procedures and be available for the duration of the study.
  3. Be a female or male aged at least 21 years.
  4. Have a diagnosis of any solid tumor type who has or is undergoing either curative or palliative treatment
  5. Have intent or interest to use cannabis to treat their symptoms.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Report of other non-prescription drug use, such as cocaine, heroin, methamphetamine in the past 60 days
  2. Actively seeking or in treatment for any substance use disorder
  3. Acute illness other than cancer that could affect cognition or compliance per the decision of the study M.D.
  4. Premenopausal females who are pregnant or trying to become pregnant. Note that pregnancy testing will not be required.
  5. A Telephone Interview for Cognitive Status (TICS) score indicating moderate or severe cognitive impairment at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03617692


Contacts
Layout table for location contacts
Contact: Angela Bryan, PhD 303-492-8264 angela.bryan@colorado.edu

Locations
Layout table for location information
United States, Colorado
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Angela Bryan, PhD    303-588-3335    angela.bryan@colorado.edu   
Principal Investigator: Angela Bryan, PhD         
University of Colorado Boulder Not yet recruiting
Boulder, Colorado, United States, 80309
Contact: Angela Bryan, PhD    303-492-8264    angela.bryan@colorado.edu   
Principal Investigator: Angela Bryan, PhD         
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: Angela Bryan, PhD University of Colorado, Denver
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03617692    
Other Study ID Numbers: 18-0836.cc
First Posted: August 6, 2018    Key Record Dates
Last Update Posted: March 9, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Colorado, Denver:
Cannabis
Tumors
Observational Study
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders